Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 1999

View Archived Issues

Progen receives provisional approval to undertake clinical studies of PI-88 at second site

KeraVision receives FDA approval to complete enrollment for phase IIIb Intacs trial

Company Profile: Immucon

CytRx initiates phase I/II study of Flocor for treatment of acute lung injury

New anticancer compound from Diatide shown to arrest tumor growth

Eisai's proton pump inhibitor approved in E.U. for GERD maintenance

New glycine antagonist added to Glaxo Wellcome's research program

New cyclopentenopyridine derivatives from Banyu active as ETA antagonists

Antibacterial quinolines developed at SmithKline Beecham

Inhibitors of matrix metalloproteinases reported in patent literature by American Cyanamid

Lotronex NDA gets priority review from FDA

AGN-194310, a high-affinity RAR antagonist for treating retinoid-induced toxicities

Dual M2 antagonism/AChE inhibition: an effective approach to treating memory disorders

Spironolactone continues to provide benefits in patients with heart failure

Oxazolidinone antibacterial agents synthesized at Bayer

MS&D's new GABA-A receptor ligands expected to be effective and safe for anxiety, etc.

Ouabain analogue LND-623 is a more effective and less toxic inotropic agent

Cerebrus presents new NMDA receptor antagonists with selectivity for cerebellum

Scotia's Foscan achieves positive results in phase III clinical trial

Non-halogen-containing PDHK inhibitors designed at Novartis

RESPECT trial will evaluate effects of lipid reduction on stroke prevention

More on Lilly's GH secretagogue program, including clinical candidate

Sulfamide inhibitors of MMPs: synthesis and pharmacological data presented at ACS meeting

p38 inhibitor RPR-200765A designated candidate for development in arthritis Rx

Nortran and Hoechst Marion Roussel to develop new antiarrhythmic compounds

New ulcer drug approved for the first time in Japan

ACS news: new compounds from Merck & Co. potently and selectively inhibit 5alpha-reductase type 1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...